NewsDialy
A Dutch court has ordered Merck to stop manufacturing and marketing the subcutaneous formulation of its cancer drug Keytruda in several European countries.
The ruling finds that Merck infringed a patent held by Halozyme Therapeutics regarding the specific delivery method for the medication.
The court's decision applies to France, Italy, Sweden, Switzerland, and the Netherlands.
This legal action is part of a broader patent infringement dispute between the two companies over Keytruda, which is described as a best-selling cancer treatment.
Keep reading